A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

3期进行中（已停止招募） NCT05528510

适应症	Colitis, Ulcerative
分期	3期
申办方	Janssen Research & Development, LLC
状态	进行中（已停止招募）
受试者人数	418 人
干预（药物）	Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3
开始日期	2022年9月13日
完成日期	2024年4月2日
结果公布日	2025年12月9日

摘要

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).

Percentage of Participants in Clinical Remission at Week 12

Week 12 · Percentage of participants

Placebo	6.5 Percentage of participants
Combined Guselkumab 400 mg	27.6 Percentage of participants

p-value	<0.001
Adjusted Treatment Difference	21.1 (95% CI 14.5–27.6)

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
GI Permeability Change in Response to Aquamin® — James Varani
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University
ENhanced Recovery in CHildren Undergoing Surgery — Northwestern University

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский